All News

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

As a cancer survivor, I talk about where to look for the light when in utter darkness.

Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.

The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.

Treatment with thermal ablation was noninferior to surgical resection in small-size colorectal liver metastases, according to the COLLISION trial.

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

A revelation has given me perspective for the New Year, inspiring me to embrace change, set new goals and upgrade myself to a better version in 2025.

Dr. Andreas M. Kaiser explains how a colostomy may preserve a patient’s health and help to avoid colorectal cancer complications.

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies across kidney, bladder and prostate cancers.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.